SBUX
37
-2
RHI
57
-6
MTCH
20
-8
DLTR
38
-4
CMS
60
2
RL
69
-4
NOV
52
-5
MCD
52
-5
REGN
38
-2
STX
45
-4
T
48
3
IPG
34
-9
ESS
62
-3
FOX
51
-6
HSIC
45
5
EXR
57
2
URBN
48
-6
MMM
35
-5
CL
54
3
TEL
60
-8
SBUX
37
-2
RHI
57
-6
MTCH
20
-8
DLTR
38
-4
CMS
60
2
RL
69
-4
NOV
52
-5
MCD
52
-5
REGN
38
-2
STX
45
-4
T
48
3
IPG
34
-9
ESS
62
-3
FOX
51
-6
HSIC
45
5
EXR
57
2
URBN
48
-6
MMM
35
-5
CL
54
3
TEL
60
-8
Financhill
Back

John Hancock Premium Div Fund Vs. Halozyme Therapeutics Industry Stock Comparison

Sell
50

PDT
John Hancock Premium Div Fund

Last Price:
12.67
Seasonality Move:
3.38%
Sell
39

HALO
Halozyme Therapeutics

Last Price:
45.65
Seasonality Move:
17.03%
Sell
50
John Hancock Premium Div Fund (PDT) is a Sell

Is John Hancock Premium Div Fund a Buy, Sell or Hold?

  • The current John Hancock Premium Div Fund [PDT] share price is $12.67. The Score for PDT is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
  • PDT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
39
Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics a Buy, Sell or Hold?

  • The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
  • HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

PDT Stock Price Chart

What is John Hancock Premium Div Fund's stock price today?

  • The John Hancock Premium Div Fund share price today is $12.67
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and PDT is experiencing slight selling pressure.

HALO Stock Price Chart

What is Halozyme Therapeutics's stock price today?

  • The Halozyme Therapeutics share price today is $45.65
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.

PDT Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.11 Sell
Relative Strength Index (14 RSI): 39.42 Sell
Chaikin Money Flow: -44720 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (12.76 - 13.2) Sell
Bollinger Bands (100): (12.09 - 13.31) Sell

HALO Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.02 Sell
Relative Strength Index (14 RSI): 30.2 Sell
Chaikin Money Flow: -7140517 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (49.94 - 58.56) Sell
Bollinger Bands (100): (52.16 - 60.38) Sell

PDT Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 12.88 Sell
20-day SMA: 12.93 Sell
50-day SMA: 13.17 Sell
200-day SMA: 12.06 Buy
8-day EMA: 12.8 Sell
20-day EMA: 12.92 Sell
50-day EMA: 12.96 Sell
200-day EMA: 12.25 Buy

HALO Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 57.53 Sell
20-day SMA: 54.48 Sell
50-day SMA: 56.18 Sell
200-day SMA: 48.93 Sell
8-day EMA: 55 Sell
20-day EMA: 55.41 Sell
50-day EMA: 55.64 Sell
200-day EMA: 50.73 Sell

John Hancock Premium Div Fund Earnings Growth & PDT Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.

Halozyme Therapeutics Earnings Growth & HALO Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.

John Hancock Premium Div Fund Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Halozyme Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):